US2023172815A1PendingUtilityA1

Antifungal solution and foot wipe

Assignee: PELLI SKIN CO LLCPriority: Mar 15, 2018Filed: Feb 1, 2023Published: Jun 8, 2023
Est. expiryMar 15, 2038(~11.6 yrs left)· nominal 20-yr term from priority
A61K 8/466A61Q 17/005A61K 8/46A61K 31/325A61K 31/357D21H 21/36A61K 8/42A61K 8/9789A61K 9/0014A61K 9/7007A61K 8/4973A61K 8/922A61K 8/0208
70
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A treatment solution includes a carrier liquid, and an antifungal agent comprising on of tolnaftate, terbinafine hydrochloride, and miconazole nitrate, the antifungal agent having a concentration of at least 1 wt % of the solution, wherein the treatment solution is alcohol free.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A treatment solution, comprising:
 a carrier liquid; and   an antifungal agent comprising on of tolnaftate, terbinafine hydrochloride, and miconazole nitrate, the antifungal agent having a concentration of at least 1 wt % of the solution,   wherein the treatment solution is alcohol free.   
     
     
         2 . The treatment solution as claimed in  claim 1 , wherein the carrier fluid comprises water and one of either ethylene glycol or polyethylene glycol. 
     
     
         3 . The treatment solution as claimed in  claim 1 , further comprising an antifungal agent solvent. 
     
     
         4 . The treatment solution as claimed in  claim 3 , wherein the antifungal agent solvent comprises a heterocyclic acetyl solvent. 
     
     
         5 . The treatment solution as claimed in  claim 4 , wherein the heterocyclic acetyl solvent comprises dioxolane. 
     
     
         6 . The treatment solution as claimed in  claim 1 , further comprising one or more of an emollients, surfactants, texture enhancers or texturizers, moisturizers, solvents, anti-inflammatory agents, deodorants, anti-bacterial, and curative ingredients, wherein curative ingredients are selected to provide at least one of improved texture, skin nourishment, reduced infections, and increased circulation. 
     
     
         7 . The treatment solution as claimed in  claim 1 , further comprising one or more essential oils. 
     
     
         8 . The treatment solution as claimed in  claim 7 , wherein the one or more essential oils are selected from  eucalyptus , peppermint oil, chamomile oil, geranium oil, juniper oil, sandalwood oil, rose oil, lavender oil, and tea tree oil. 
     
     
         9 . The treatment solution as claimed in  claim 1 , further comprising at least one of glycerin,  gossypium herbaceum  (cotton seed oil), polyglyceryl-4 laurate, dilaurly citrate, ethylexyl stearate, caprylyl glycol (a combination of  gossypium herbaceum (cotton seed oil), polyglyceryl-4 laurate, dilaurly citrate, and ethylexyl stearate. 
     
     
         10 . The treatment solution as claimed in  claim 1 , further comprising at least one of vitamin E, vitamin E esters and salts thereof, tocopheryl acetate, tocopheryl succinate, tocopheryl nicotinate, tocopheryl linolate, and alpha-tocopheryl phosphates. 
     
     
         11 . The treatment solution as claimed in  claim 1 , further comprising at least one of sodium lauroyl sarcosinate, sodium laurylamphoacetate, and sorbitan laurate. 
     
     
         12 . The treatment solution as claimed in  claim 1 , further comprising one of a lotion, a cream, a spray, or a wipe that contains the treatment solution.

Join the waitlist — get patent alerts

Track US2023172815A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.